TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01852110

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AChEI
Description: One of the following AChEIs, as prescribed by the participant's primary care physician:~Donepezil: 10 mg total daily dose, administered orally~Rivastigmine: 9.5 or 13.3 mg/24 hours, administered by transdermal patch; or 6-12 mg total daily dose administered orally~Galantamine: 16-24 mg total daily dose, administered orally
Study: NCT03876886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin 90mg/m2 iv d1 or divide into two days
Study: NCT02559245

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Descurainia Sophia

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ficus carica
Study: NCT01045720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Suo Quan Wan, Wu Lin San
Description: Suo Quan Wan Wu Lin San Placebo 2/daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (starch)
Study: NCT01523860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Mitoxantrone, Bendamustine
Description: Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
Study: NCT04666051

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Application of fibrin glue sealant
Study: NCT02674529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Selective Serotonin Reuptake Inhibitor (SSRI)
Study: NCT03876886

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: cyclophosphamide600mg/m2 iv d1,q14d\*4cycles;with G-CSF support: 3ug/kg ih

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2 iv d1, q14d\*4cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin AUC=3 iv d2, q14d\*8cycles;with G-CSF support: 3ug/kg ih

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175mg/m2 iv d1, q14d\*8cycles
Study: NCT03234478

Intervention type: OTHER
Intervention: cognitive assessments
Description: Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement

Intervention type: OTHER
Intervention: cognitive assessments
Description: Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
Study: NCT02831738

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Polydextrose
Description: Polydextrose 12 g

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control Treatment
Description: no polydextrose
Study: NCT00831740

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Speech and Language Therapy (SLT)
Description: Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention Control
Description: Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
Study: NCT02359357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study: NCT02674529

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Real-time Neurofeedback fMRI task pre- and post-RCT
Description: Placebo experiment during an fMRI scanning session

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Real-time Neurofeedback fMRI task pre- and post-RCT
Description: Placebo experiment during an fMRI scanning session
Study: NCT02891850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sildenafil
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil
Description: Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
Study: NCT02422511

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Description: Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
Study: NCT00893555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: TDM (through level of 2-5mg/L).
Study: NCT02359357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169
Study: NCT02422511

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genomic sequencing
Description: Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Family history report
Description: Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
Study: NCT02924779

Intervention type: OTHER
Intervention: No intervention
Description: Retrospective observational study
Study: NCT00139399

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Description: Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass graft (CABG) surgery
Description: Patients were randomized to receive either a radial artery or a long saphenous vein graft to the left circumflex coronary artery territory during CABG surgery
Study: NCT04169321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single Arm
Description: \[68Ga\]-NOTA-hGZP is a PET imaging agent.
Study: NCT04044612

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medial Unloader Brace
Description: medial knee unloader braces use a three point bending system to increase space in the medial tibiofemoral compartment during weight bearing
Study: NCT02961751

Intervention type: DRUG
Group type: OTHER
Intervention: Ciprofloxacin
Description: Directly observed treatment with a single dose of ciprofloxacin 500 mg orally with or without food.
Study: NCT02359357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDL169

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03604588

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: HPV OncoTect™
Description: Salivary specimens will be collected from 40 patients with oropharyngeal cancer The saliva samples will be sent to incell dx, which will analyze them blindly (without knowledge of the clinicopathological information) with the HPV OncoTect ™ test.~Clinical and pathological information will be collected and maintained by the principal investigator At the end of the study, the results obtained with the HPV OncoTect ™ test will be confronted with the clinical and pathological results.
Study: NCT01838330

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: psyllium
Description: 15 grams/day for 1 week, followed by 30 grams/day for 4 months
Study: NCT02320812

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human retinal progenitor cells
Description: single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
Study: NCT04502420

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function before and after surgery
Description: A diagnostic test
Study: NCT02298803

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter and Glucose monitoring
Description: (i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.~(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities.
Study: NCT00893555

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: voriconazole (dosing according to the SPC)
Description: No serum concentrations are determined
Study: NCT02383043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cocaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sustained Release d-Amphetamine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sustained Release d-Amphetamine
Study: NCT01571050

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Purified water
Description: Ingestion of 30 mL of purified water
Study: NCT06100159

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tube insertion
Description: Ventilation tube insertion in the tympanic membrane
Study: NCT01571050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh MFP/CaCO3 toothpaste
Description: Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fresh NaF/SiO2 toothpaste
Description: Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged NaF/SiO2 toothpaste
Description: Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aged MFP/CaCO3 toothpaste
Description: Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
Study: NCT03003221

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AIR-P Dental Toolkit
Description: The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AIR-P Dental Toolkit
Description: The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Training
Description: The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
Study: NCT02227953

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham-Yband (YDT-201N)
Description: transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
Study: NCT00769925

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy-Primary Care
Description: Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapist-Assisted Bibliotherapy-Primary Care
Description: Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
Study: NCT03392389

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1653
Description: Escalating dose levels

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT01261442

Intervention type: PROCEDURE
Intervention: Nerve Conduction Study (NCS)
Description: An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.

Intervention type: PROCEDURE
Intervention: Nerve Conduction Study (NCS)
Description: An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
Study: NCT03316664

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Neurocognitive Therapy (INT)
Description: Information already included in arm/group description.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Integrated Psychological Therapy (IPT)
Description: Information already included in arm/group description.

Intervention type: OTHER
Group type: OTHER
Intervention: COGPACK
Description: Information already included in arm/group description.
Study: NCT02927080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.
Study: NCT01131468

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
Study: NCT02927080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACE-083
Description: Recombinant fusion protein.
Study: NCT05002439

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program and a nutritional intervention
Description: The exercise program will be delivered by trained experts in groups of 6 participants, and will be based on the recommendations presented in the Spanish Healthcare Ministry document. This program includes balance, flexibility, and strength and power exercises. The program will be realized twice a week, during 45 minutes time, for 16 weeks, twice a year. Nutritional intervention will be based on the results of MNA-SF. If the results of this instrument show normal nutrition status, general nutritional recommendations will de presented by a nutritionist twice a year before the physical exercise program. If MNA-SF shows nutritional risk or malnutrition, oral nutritional supplementation will be offered. Primary Care Physicians will have the opportunity of referring high risk participants to their Geriatrics Department Participants when appropriate, following Healthcare Ministry algorithm
Study: NCT04171141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07062119
Description: PF-07062119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1
Description: Anti-PD1 PF-06801591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1
Description: Anti-PD1 PF-06801591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD1
Description: Anti-PD1 PF-06801591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Anti-VEGF IV (bevacizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Anti-VEGF IV (bevacizumab)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-VEGF
Description: Anti-VEGF IV (bevacizumab)
Study: NCT03909282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumpectomy
Description: Standard of Care surgery for DCIS (either lumpectomy or mastectomy)
Study: NCT01868620

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iontophoretic CXL

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard CXL
Study: NCT03876015

Intervention type: DRUG
Intervention: Semaglutide
Description: Patients will be treated with commercially available semaglutide in a prefilled pen injector (FlexTouch® variant) according to routine local clinical practice at the discretion of the treating physician. Other anti-hyperglycaemic treatments will be prescribed at the physician's discretion.
Study: NCT01375868

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Silgard
Description: vaccination with tetravalent antiviral vaccine
Study: NCT02023801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aurora Endometrial Ablation System
Description: Ablation of the endometrial lining of the uterus using the Aurora System
Study: NCT02489708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cessation Counseling
Description: Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
Study: NCT02241811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% Sodium Pentaborate Pentahydrate
Description: For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Hydrogel without 3% Sodium Pentaborate Pentahydrate
Study: NCT02125916

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oxygen therapy
Study: NCT05062304

Intervention type: DRUG
Intervention: Fluticasone Furoate-Vilanterol Trifenatate
Description: Fluticasone Furoate-Vilanterol Trifenatate dispensing claim is used as the reference group.

Intervention type: DRUG
Intervention: Furoate-umeclidinium-vilanterol
Description: Furoate-umeclidinium-vilanterol dispensing claim is used as the exposure group.